Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the

① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.

cls.cn21:09 ET

While Individual Investors Own 30% of Shanghai Shyndec Pharmaceutical Co., Ltd. (SHSE:600420), Private Companies Are Its Largest Shareholders With 58% Ownership

Simply Wall StFeb 13 18:04 ET

Shyndec Pharma's Units Get Three Drug Registration Certificates

MT NewswiresJan 22 05:40 ET

Shanghai Shyndec's Shenzhen Unit Passes EU GMP Inspection

MT NewswiresJan 20 00:42 ET

Shyndec Pharma Unit's Cefuroxime Sodium for Injection Passes Regulatory Consistency Evaluation

MT NewswiresJan 20 00:23 ET

Sinopharm Hyundai: 2024 Annual Performance Forecast

SZSIJan 19 11:00 ET · Announcements